Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative
Revision as of 11:39, 27 March 2019 by 84.250.17.211 (talk) (Remove now unnecessary 1px width hack from table footer cell)
| Event | Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI[note 1]) | Placebo (n = 8102) |
CEEs/MPA (n = 8506) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Absolute Risk per 10,000 Women-Years | |||||||||
| Coronary heart disease events ( non-fatal myocardial infarction, death) |
1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) |
30 23 6 |
37 30 7 | ||||||
| Invasive breast cancer[lower-alpha 1] | 1.26 (1.00–1.59) | 30 | 38 | ||||||
| Stroke | 1.41 (1.07–1.85) | 21 | 29 | ||||||
| Pulmonary embolism | 2.13 (1.39–3.25) | 8 | 16 | ||||||
| Colorectal cancer | 0.63 (0.43–0.92) | 16 | 10 | ||||||
| Endometrial cancer | 0.83 (0.47–1.47) | 6 | 5 | ||||||
| Hip fracture | 0.66 (0.45–0.98) | 15 | 10 | ||||||
| Death due to causes other than above | 0.92 (0.74–1.14) | 40 | 37 | ||||||
| Global Index[lower-alpha 2] | 1.15 (1.03–1.28) | 151 | 170 | ||||||
| Deep vein thrombosis[lower-alpha 3] | 2.07 (1.49–2.87) | 13 | 26 | ||||||
| Vertebral fractures[lower-alpha 3] | 0.66 (0.44–0.98) | 15 | 9 | ||||||
| Other osteoporotic fractures[lower-alpha 3] | 0.77 (0.69–0.86) | 170 | 131 | ||||||
| Sources: [1][2] | |||||||||
| This template's documentation is missing, inadequate, or does not accurately describe its functionality and/or the parameters in its code. Please help to expand and improve it. (March 2019) |
Notes and references
- ↑ Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
- ↑ Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.
- ↑ Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
- ↑ A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
- ↑ 3.0 3.1 3.2 Not included in Global Index.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |
Cite error: <ref> tags exist for a group named "note", but no corresponding <references group="note"/> tag was found, or a closing </ref> is missing